The CDK4/6 inhibitor market for breast cancer has changed from a monopoly to a duopoly in Korea. Kisqali, which had been introduced later into the market, has nearly caught up with Ibrance's sales.

According to the market research institution IQVIA on the 24th, sales of Novartis’s Kisqali had risen 95.2% YoY to reach KRW 12.1 billion in Q3 this year. During the same period, Pfizer’s Ibrance posted sales of KRW 12.3 billion, down 12.1% YoY from the KRW 14 billion it posted in Q3 last year.

The cyclin-dependent kinases (CDK) 4/6 inhibitors selectively inhibit the CDK4(cyclin-dependent kinase 4) and CDK6(cyclin-dependent kinase 6) enzymes that regulate cell division and cell growth to block t